Albany, NY -- (SBWIRE) -- 06/20/2014 -- Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends wrong signals. Seizures could differ from primary generalized seizures to partial seizures depending upon the cause of the epilepsy. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages.
Browse Full Report with TOC: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html
For the treatment of epilepsy, doctors prescribe antiepileptic medicines (AEDs) and the preference for the drug depends on the type of seizures to be treated, age of the patient, part of the brain involved and seriousness of the seizures. On the basis of the available AEDs, epilepsy therapeutics market is segmented into two major categories namely first generation AEDs and second generation AEDs. First generation AEDs consist of following drugs:
- Carbamazepine (Carbatrol)
- Valproate (Depakote)
- Oxycarbazepine ((Trileptal)
- Phenytoin (Dilantin, Phenytek)
- Ethosuximide (Zarontin)
- Phenobarbital (Luminal)
- Primidone (Mysoline)
- Topiramate (Topamax)
Second generation AEDs consist of medicines with different mechanism of action than the first generation drugs. This segment of epilepsy therapeutics market consists of following drugs:
- Pregabalin (Lyrica)
- Lamotrigine (Lamictal)
- Levetiracetam (Keppra)
- Zonisamide (Zonegran)
- Lacosamide (Vimpat)
- Eslicarbazepine acetate (Aptiom/Zebinix)
- Perampanel (Fycompa)
- Ezogabine/retigabine (Trobalt/Potiga)
- Rufinamide (Banzel/Inovelon)
First generation AEDs majorly carbamazepine, valproate, phenytoin and oxycarbazepine dominates the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the epilepsy therapeutics market due to its improved efficacy and tolerability. Additionally, large number of research and development activities, are going on all over the world for the development of antiepileptic medicines with diverse mechanism actions. As for instance two major players of epilepsy therapeutics market namely UCB Pharma Ltd. and Marinus Pharmaceuticals, Inc. has developed brivaracetam and ganaxolone respectively, for treating epilepsy. Both of these drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.
North America leads the epilepsy therapeutics market followed by Europe majorly due to the extensive research and development activities and availability of second generation drugs. Three new AEDs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate and it expected that brivaracetam will be approved soon. Ezogabine/retigabine and perampanel among these have novel mechanism of action and thus it is capturing good amount of market share in U.S. Continuous increase in uptake of second generation AEDs is also driving the epilepsy therapeutics market in North America and Europe. Asia-Pacific is also increasing at faster pace for epilepsy therapeutics market. High prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market in this region.
Some of the major players in epilepsy therapeutics market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Read More Reports on Pharmaceutical Markets: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448
Latest Upcoming Reports: http://www.transparencymarketresearch.com/upcoming.htm
Follow In LinkedIn: https://www.linkedin.com/today/post/article/20140618093038-263590413-epilepsy-therapeutics-market
90 State Street,
Albany NY - 12207
Browse Market Research Blogs: